[To learn English] Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer. The drugmaker will release third quarter results on Wednesday, the first for Mike Doustdar who was tasked in August with turning around the Danish company's fortunes. 诺和诺德新任首席执行官本周将面临投资者的密切关注，这家Wegovy的生产商正在重组董事会，并与美国竞争对手辉瑞展开竞购战。 这家制药公司将于周三公布第三季度业绩，这将是迈克·杜斯塔尔(Mike Doustdar)上任后的首份业绩报告。他于8月受命扭转这家丹麦公司的颓势。 LearnEnglishLeave a remark
